Last reviewed · How we verify

Accordion Pill™ Carbidopa/Levodopa

Intec Pharma Ltd. · Phase 3 active Small molecule

The Accordion Pill™ is a modified-release formulation that delivers carbidopa and levodopa sequentially to optimize absorption and reduce motor fluctuations in Parkinson's disease.

The Accordion Pill™ is a modified-release formulation that delivers carbidopa and levodopa sequentially to optimize absorption and reduce motor fluctuations in Parkinson's disease. Used for Parkinson's disease with motor fluctuations.

At a glance

Generic nameAccordion Pill™ Carbidopa/Levodopa
Also known asAP CD/LD, AP-CD/LD
SponsorIntec Pharma Ltd.
Drug classDopamine precursor with peripheral decarboxylase inhibitor
TargetAromatic L-amino acid decarboxylase (carbidopa); dopamine pathway (levodopa)
ModalitySmall molecule
Therapeutic areaNeurology
PhasePhase 3

Mechanism of action

Levodopa is converted to dopamine in the brain to replace depleted neurotransmitter in Parkinson's disease, while carbidopa inhibits peripheral decarboxylation of levodopa, allowing more to reach the brain. The Accordion Pill's accordion-shaped design expands in the stomach and releases the drugs in a controlled, sequential manner to maintain more stable plasma levels and reduce on-off motor symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: